Abstract
One strategy to address hyperprolactinemia and associated sexual side effects in patients receiving antipsychotics is switching to an antipsychotic not associated with prolactin elevation (eg, aripiprazole). This post hoc analysis assessed prolactin concentrations and sexual side effects in an open-label prospective study of switching long-acting injectable antipsychotics from paliperidone palmitate (PP) to aripiprazole lauroxil (AL). Serum prolactin was measured throughout the study. Patient-reported sexual and endocrine side effects were assessed on the UKU Side Effect Rating Scale sexual function subscale and analyzed in study completers. Prior to starting AL treatment (screening), 49/50 (98%) patients had prolactin concentrations above the upper limit of normal (ULN; >13.13 ng/mL [males]; >26.72 ng/mL [females]). Six months after beginning AL treatment, prolactin levels were above ULN in 2/32 (6.3%) patients. Among 32 study completers, 81.3% reported sexual dysfunction in ≥1 domain at screening versus 56.3% at 6 months after starting AL treatment. Diminished sexual desire was the most common patient-reported sexual complaint at screening (46.9%); at 6 months, it was reported by 18.8%. In this post hoc analysis, the high lev...Continue Reading
References
Aug 1, 1983·Journal of the American Geriatrics Society·A WeizmanM Ben David
Mar 26, 2003·Psychoneuroendocrinology·Bruce J KinonUriel M Halbreich
Jan 28, 2004·The Journal of Clinical Psychiatry·Jan VolavkaJeffrey A Lieberman
Jun 18, 2005·The Journal of Clinical Psychiatry·Kristina Melkersson
Feb 28, 2007·Vascular Health and Risk Management·Thorsten Reffelmann, Robert A Kloner
Mar 1, 2008·Journal of Psychopharmacology·Amna MirKatherine J Aitchison
Mar 15, 2008·Human Psychopharmacology·Martin Baggaley
Oct 14, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mong-Liang LuChun-Hsin Chen
Dec 31, 2008·Pharmacotherapy·Jolene R BostwickVicki L Ellingrod
Jan 13, 2009·Acta Psychiatrica Scandinavica. Supplementum·P E BebbingtonM Toumi
Sep 4, 2010·Journal of Clinical Psychopharmacology·Norio Yasui-FurukoriSunao Kaneko
Aug 9, 2011·Journal of Women's Health·James A Simon
Dec 23, 2011·Advances in Urology·Erik JohnsenHugo A Jørgensen
Mar 22, 2012·BMC Psychiatry·Marco DibonaventuraEdward Kim
Jun 4, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Takashi TsuboiHiroyuki Uchida
Jun 6, 2013·Pharmacopsychiatry·A La TorreM Grözinger
Oct 8, 2013·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·John M KaneChristoph U Correll
Feb 28, 2015·Schizophrenia Bulletin·Marrit K de BoerHenderikus Knegtering
Aug 11, 2016·Psychotherapy and Psychosomatics·André F CarvalhoGiovanni A Fava
Jun 19, 2018·Journal of Clinical Psychopharmacology·Deanna L KellyJoseph P McEvoy
Sep 17, 2018·Current Obesity Reports·David B SarwerKristine Steffen
Feb 13, 2019·Schizophrenia Research·Brian J MillerSteven G Potkin
May 7, 2019·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Taishiro KishimotoChristoph U Correll
Jul 16, 2019·Lancet·Maximilian HuhnStefan Leucht